Zacks Investment Research upgraded shares of electroCore (NASDAQ:ECOR) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. The firm currently has $1.75 price objective on the stock.
According to Zacks, “Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. “
Other analysts have also recently issued research reports about the stock. Evercore ISI reissued a buy rating and set a $24.00 target price on shares of electroCore in a research note on Tuesday, August 13th. JMP Securities cut their target price on shares of electroCore to $10.00 and set a positive rating for the company in a research note on Thursday, August 15th. Noble Financial reissued a buy rating and set a $11.00 target price on shares of electroCore in a research note on Thursday, August 15th. BTIG Research reissued a hold rating on shares of electroCore in a research note on Wednesday, August 14th. Finally, ValuEngine raised shares of electroCore from a hold rating to a buy rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. electroCore currently has an average rating of Buy and a consensus target price of $11.15.
electroCore (NASDAQ:ECOR) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. The business had revenue of $0.62 million during the quarter. electroCore had a negative net margin of 4,450.22% and a negative return on equity of 90.27%. On average, analysts expect that electroCore will post -1.3 earnings per share for the current year.
In other electroCore news, Director Thomas J. Errico acquired 18,974 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $1.62 per share, with a total value of $30,737.88. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Thomas J. Errico acquired 21,000 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The shares were acquired at an average cost of $1.77 per share, with a total value of $37,170.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 49,974 shares of company stock valued at $85,108. 43.78% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ECOR. Rockefeller Capital Management L.P. purchased a new stake in electroCore during the 2nd quarter valued at about $28,000. Bronfman E.L. Rothschild L.P. purchased a new stake in electroCore during the 2nd quarter valued at about $50,000. Valeo Financial Advisors LLC grew its stake in electroCore by 101.6% during the 2nd quarter. Valeo Financial Advisors LLC now owns 26,000 shares of the company’s stock valued at $52,000 after acquiring an additional 13,100 shares in the last quarter. Rhumbline Advisers purchased a new stake in electroCore during the 1st quarter valued at about $73,000. Finally, Brighton Jones LLC grew its stake in electroCore by 49.2% during the 2nd quarter. Brighton Jones LLC now owns 45,471 shares of the company’s stock valued at $91,000 after acquiring an additional 15,000 shares in the last quarter. 15.52% of the stock is owned by institutional investors.
electroCore, Inc, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.